Osimertinib for advanced non-small cell lung cancer harboring EGFR mutation exon 20 T790M, acquired resistant mutation for first- or second-generation EGFR-TKI.

ABSTRACT:

SUBMITTER: Okuma Y 

PROVIDER: S-EPMC5394089 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature